Ben-gurion University of the Negev Research and Development Authority

Hadasit Medical Research Services and Development Ltd.

B.g. Negev Technologies and Applications Ltd.

Teva Pharmaceutical Industries Limited

Pharmedica Ltd.

Polyrizon Ltd.

Smadar Cohen

Jonathan Leor

Yaron Ilan

Eyal Shteyer

Ami Ben-Ya'Acov

Lilia Shapiro

Rachel Glicklis

Gadi Lalazar

Tsiona Elkayam

Ashraf Brik

Emil Ruvinov

Eyal S Ron

Robert Steven Marks

Alon Monsonego

Yoram Rubin

Inbar Freeman

Michal Shachar

Esther Lobel

Olga Kryukov

Sigalit Shaprut

Anat Perets

Sharon Etzion

Ayelet Dar

Tali Re'Em

Tal Dvir

Efrat Forti

Tomer Izraeli

Stav Shamir

Mona Dvir-Ginzberg

Ami Ben-Yaakov

The invention relates generally to compositions and methods for generating immunotolerant responses in a subject. Specifically, the invention relates to a composition comprising a sulfated polysaccharide and a bioactive polypeptide for generating an immunotolerant response.

Methods for generating immunotolerant responses

The present invention relates to site-selective modification of polysaccharides at their reducing end by conjugation with a single aminoxy-Regioselective Addressable Functionalized Template (RAFT) peptide.

Site-selective modification of polysaccharides and applications thereof

Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than &#x2212;25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10cm/second, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease; liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.

Alginate compositions and uses thereof

The present invention provides an anionic polyplex formed from a nucleic acid and an anionic polymer and further comprising a cation, which can be in the form of a nanoparticle or a microparticle and compositions comprising the anionic polyplex. The present invention further provides uses of the anionic polyplex such as delivery of the nucleic acid into cells and methods of treating a disease, disorder or condition selected from the group consisting of cancer, a metabolic, a neurodegenerative, a cardiovascular, and an infectious or inflammatory disease or disorder. The present invention also provides an anionic complex comprising a divalent cation and a nucleic acid but lacking an anionic polymer, in the form of a nanoparticle that is capable of forming a colloidal suspension.

Anionic polyplexes for use in the delivery of nucleic acids

The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.

Alginate biomaterials for the treatment of hepatic disorders

Provided are orally administrable thin film dosage forms adapted to adhere to a mucosal tissue of a patient, wherein said film comprises mixtures of polymers and insulin.

Oral dissolving films for insulin administration, for treating diabetes

Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.

Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent

The present invention provides a multi-compartment hydrogel, and a sulfated polysaccharide and at least two bioactive polypeptides capable of binding said sulfated polysaccharide, for use in repair or regeneration of a damaged tissue in a mammal. Also provided is a method for constructing the multi-compartment hydrogel. The present invention also provides a method for the repair or regeneration of a damaged tissue in a mammal, and a kit for constructing a multi-compartment hydrogel.

Hydrogel system comprising spatially separated bioactive polypeptides

The present invention relates to bioresorbable scaffolding for tissue regeneration or repair. The present invention describes an epithelial organoid comprising an aggregate of epithelial cells predominantly expressing markers associated with differentiated cell types, and an aggregate which assumes a structure or performs a function associated with an epithelial organ or a fragment thereof. The present invention also provides a method of treating a subject in need of repair or replacement of an organ or a portion thereof; and/or a method of treating a subject with a disease or disorder which impairs or abrogates a liver, kidney, pancreas, thyroid or pituitary function. The present invention also describes an epithelial graft or artificial organ comprising spheroids, organoids or a combination thereof, and a kit for implantable epithelial graft formation comprising organoids.

Scaffolding for tissue regeneration or repair

A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Injectable cross-linked polymeric preparations and uses thereof

The present invention provides novel mucoadhesive compounds useful in the prevention of diseases and disorders of or which are associated with the mucosal membrane.

Method for removal of toxins from mucosal membranes

Growing community of inventors

Beer-Sheva, Israel

Smadar Cohen